Standout Papers
- Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC (2021)
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021)
- Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023)
Immediate Impact
9 from Science/Nature 62 standout
Citing Papers
Cefepime–Taniborbactam in Complicated Urinary Tract Infection
2024 Standout
Natural killer cell therapies
2024 StandoutNature
Works of Erin Jensen being referenced
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
2021
Ertapenem versus Cefotetan Prophylaxis in Elective Colorectal Surgery
2006
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Erin Jensen | 384 | 1323 | 234 | 816 | 53 | 2.0k | |
| Naoki Ishizuka | 548 | 805 | 210 | 687 | 111 | 1.9k | |
| Gottfried J. Locker | 331 | 627 | 598 | 678 | 113 | 2.3k | |
| Thomas R. Fleming | 606 | 1420 | 359 | 594 | 30 | 2.7k | |
| Montserrat Fraga | 200 | 1309 | 344 | 391 | 50 | 2.1k | |
| Patricia M. de Groot | 291 | 1064 | 206 | 1112 | 54 | 2.5k | |
| Hassan Izzedine | 249 | 504 | 141 | 697 | 91 | 2.0k | |
| Reury-Perng Perng | 319 | 1052 | 243 | 1538 | 74 | 2.3k | |
| William P. Vaughan | 221 | 857 | 399 | 607 | 86 | 2.8k | |
| Ernesto Pozzi | 243 | 404 | 233 | 1173 | 77 | 2.1k | |
| Robert E. Falcone | 730 | 830 | 185 | 408 | 61 | 2.5k |
All Works
Loading papers...